| In millions, except per share items | Sep-30-22 | Sep-30-21 | Jun-30-21 | Dec-31-20 | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues: | | | | | | | | |
| Grants and contracts | 0.7 | 0.2 | | | 0.0 | 0.1 | 0.2 | 0.4 |
| Grants and contracts growth | 183.5% | 441.9% | -100.0% | -100.0% | -83.8% | -77.2% | -21.2% | 56.5% |
| Cost of goods sold | 0.2 | 0.1 | | | | | | |
| Gross profit | 0.5 | 0.1 | | | | | | |
| Gross margin | 74.7% | 51.0% | | | | | | |
| |
| Operating expenses: | | | | | | | | |
| Research and development | 0.2 | 3.4 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 |
| Sales and marketing expense | 0.0 | 0.0 | | | | | | |
| General and administrative | 1.8 | 6.3 | 0.6 | 0.6 | 0.7 | 0.5 | 0.4 | 0.4 |
| Total operating expenses | 2.0 | 9.8 | 0.7 | 0.8 | 0.8 | 0.7 | 0.6 | 0.6 |
| Loss from operations | -1.5 | -9.6 | -0.7 | -0.8 | -0.8 | -0.6 | -0.4 | -0.3 |
| Operating margin | -230.6% | -4077.5% | | | -1771.3% | -936.2% | -284.8% | -76.1% |
| |
| Other expense: | | | | | | | | |
| Interest and other expense | -1.8 | -3.1 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | -0.4 |
| Total other expense | -1.8 | -3.1 | 0.0 | 0.1 | 0.0 | 0.7 | -0.2 | -0.8 |
| Income from discontinued operations, net of income taxes | | 0.0 | | | | | | |
| Net loss | -3.4 | -12.7 | -0.7 | -0.7 | -0.8 | -0.4 | -0.6 | -0.7 |
| Net loss attributable to noncontrolling interests | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net loss attributable to Statera Biopharma, Inc. | -3.3 | -12.7 | -0.7 | -0.7 | -0.7 | -0.4 | -0.6 | -0.7 |
| |
| Net loss attributable to common stockholders per share of common stock, basic and diluted | ($0.07) | ($0.47) | ($0.04) | ($0.05) | ($0.06) | ($0.03) | ($0.05) | ($0.06) |
| |
| Weighted average number of shares used in calculating net loss per share, basic and diluted | 50.2 | 27.0 | 15.5 | 12.4 | 13.0 | 11.9 | 11.4 | 11.3 |